NovoCure (NVCR) Current Deferred Revenue (2015 - 2019)

NovoCure (NVCR) has reported Current Deferred Revenue for 5 consecutive years, with $19.6 million the latest figure, recorded in Q4 2019.

• Quarterly Current Deferred Revenue rose 4.32% year-over-year to $19.6 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $19.6 million (up 4.32% YoY) and the FY2019 annual result came in at $19.6 million, up 4.32% from the prior year.
• Current Deferred Revenue rose to $19.6 million in Q4 2019 per NVCR's latest filing, from $18.8 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for NVCR reached as high as $19.6 million in Q4 2019 and fell as low as $52000.0 in Q4 2015.
• A 5-year average of $9.1 million and a median of $5.0 million in 2017 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2016 — Current Deferred Revenue soared 4259.62% — and 2019, when it gained 4.32%.
• Year by year, Current Deferred Revenue stood at $52000.0 in 2015, then surged by 4259.62% to $2.3 million in 2016, then jumped by 118.75% to $5.0 million in 2017, then surged by 278.48% to $18.8 million in 2018, then gained by 4.32% to $19.6 million in 2019.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $19.6 million, $18.8 million, and $5.0 million for Q4 2019, Q4 2018, and Q4 2017 respectively.